Justin L. Ricker
- Dermatology top 0.5%
- Cutaneous lymphoproliferative disorders research 11
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis 7
-
- Lymphoma Diagnosis and Treatment 10
- Oncology top 2%
- Colorectal Cancer Treatments and Studies 10
- Molecular Biology top 5%
- Histone Deacetylase Inhibitors Research 18
-
- Lung Cancer Treatments and Mutations 10
-
- T-cell and Retrovirus Studies 9
-
- Chronic Lymphocytic Leukemia Research 8
- Co-authors
- Stanley R. FrankelMadeleine DuvicCong ChenJudy H. ChiaoChunlei ZhangJohn F. ReillyCecilia KellyVictoria M. Richon
- Partner nations
- United StatesCanadaSingapore
In The Last Decade
Justin L. Ricker
59 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 95
- Dermatology 621
- Hepatology 543
- Pathology and Forensic Medicine 930
- Oncology 1.2k
- Molecular Biology 2.5k
Countries citing papers authored by Justin L. Ricker
This map shows the geographic impact of Justin L. Ricker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin L. Ricker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin L. Ricker more than expected).
Fields of papers citing papers by Justin L. Ricker
This network shows the impact of papers produced by Justin L. Ricker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin L. Ricker. The network helps show where Justin L. Ricker may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Justin L. Ricker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 13 | |
| 2 | 2014 | 17 | |
| 3 | 2014 | 50 | |
| 4 | Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trialbreakdown → | 2014 | 465 |
| 5 | 2011 | 24 | |
| 6 | 2011 | 54 | |
| 7 | 2011 | 3 | |
| 8 | 2009 | 15 | |
| 9 | 2009 | 54 | |
| 10 | 2009 | 9 | |
| 11 | 2009 | 73 | |
| 12 | 2008 | 139 | |
| 13 | 2008 | 32 | |
| 14 | 2008 | 167 | |
| 15 | Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphomabreakdown → | 2007 | 776 |
| 16 | 2007 | 7 | |
| 17 | 2006 | 9 | |
| 18 | 2002 | 24 | |
| 19 | 2002 | 45 | |
| 20 | 2000 | 44 |
About Justin L. Ricker
Justin L. Ricker is a scholar working on Dermatology, Hematology and Hepatology, having authored 63 papers that have together received 4.0k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (18 papers), Cutaneous lymphoproliferative disorders research (11 papers), Colorectal Cancer Treatments and Studies (10 papers), Lymphoma Diagnosis and Treatment (10 papers), Lung Cancer Treatments and Mutations (10 papers), T-cell and Retrovirus Studies (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). The work is most often cited by research in Dermatology (621 citations), Hepatology (543 citations) and Pathology and Forensic Medicine (930 citations). Justin L. Ricker has collaborated with scholars based in United States, Canada and Singapore. Frequent co-authors include Stanley R. Frankel, Madeleine Duvic, Cong Chen, Judy H. Chiao, Chunlei Zhang, John F. Reilly, Cecilia Kelly, Victoria M. Richon, Xiao Ni and Parul Hazarika. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.